GlaxoSmithKline ((GSK)), Icon Plc ((ICLR)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GlaxoSmithKline (GSK), in collaboration with Icon Plc, is conducting an open-label study titled ‘An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)’. The study aims to evaluate the long-term safety and efficacy of Belimumab in slowing lung function decline and improving quality of life for patients with SSc-ILD.
The intervention being tested is Belimumab, a drug administered subcutaneously, intended to slow disease progression and improve patient outcomes in systemic sclerosis-associated interstitial lung disease.
This Phase 3 interventional study follows a single-group assignment model without masking, as it is an open-label extension of a previous study. The primary purpose is treatment-focused, aiming to assess the drug’s long-term effects.
The study began on December 12, 2024, with the latest update submitted on June 27, 2025. These dates are crucial for tracking the study’s progress and anticipating future updates or results.
The ongoing study could influence GSK’s stock performance positively if results show significant benefits, potentially boosting investor confidence. The involvement of Icon Plc as a collaborator further underscores the study’s significance in the competitive pharmaceutical landscape.
The study is currently recruiting, with further details available on the ClinicalTrials portal.